# I-VAC Adult Learning Collaborative for COVID-19 Vaccination



Please use your first name and health center name when you join the session



Use the "chat" feature to let us know if you have a question



Please remember to mute your microphone unless speaking



If you can't connect audio via computer or lose computer audio at anytime, you can call in to session at (669) 900-6833, Meeting ID 812-8864-4528##





## Disclosures

- No one in a position to control the education content of the activity has any relevant financial disclosures with ineligible companies to disclose.
- What gets said here today may change based on new data and recommendations
  - Knowledge is shared more rapidly through ECHO










# Coronavirus in the U.S.: Latest Map and Case Count

#### New reported cases





#### COVID-19 Community Levels of All Counties in US




#### OVID-19 Community Levels in US by Cou t

| _      | Total | Percent | % Change |  |
|--------|-------|---------|----------|--|
| High   | 84    | 2.6196  | 0.19%    |  |
| Medium | 676   | 20.99%  | 1.92%    |  |
| Low    | 2460  | 76.4%   | - 2.1196 |  |

How are COVID-19 Community Levels calculated?

#### Community Transmission of All Counties in US



#### Community Transmission in US by County

|             | Total | Percent | % Change |
|-------------|-------|---------|----------|
| High        | 1515  | 47.02%  | - 1.02%  |
| Substantial | 870   | 2796    | 3.1396   |
| Moderate    | 617   | 19.15%  | - 3.07%  |
| Low         | 220   | 6.83%   | 0.96%    |

How is community transmission calculated?

## **CHICAGO** I COVID-19 Summary

**SUMMARY** 

CASES

CASES BY ZIP

**TESTS VACCINES**  **VACCINES BY ZIP** 

(?) Learn how to use this dashboard.

#### **盆 CASES**

409

Current daily avg

365 (+12%)

Prior week

710,383 Cumulative

15.1

Daily rate per

#### **HOSPITALIZATIONS**

24 V

Current daily avg

25 (-4%) Prior week

48,008 Cumulative

0.9 Daily rate per 100,000

Current daily avg

#### DEATHS

0.71 V


1.29 (-44%) Prior week


7,924


0.0

Cumulative

Daily rate per







#### **■** VACCINATIONS ADMINISTERED



5,476,119

Cumulative

Completed series

71.0%

79.3% At least one dose

Current daily avg

1.5% ↔

**EMERGENCY ROOM VISITS** 

1.5%

Prior Week




3.2% ↔


HOSPITAL BEDS IN USE 1


3.2%

Current daily avg

Prior Week







Data are updated M-F at 5:30 p.m., except for City holidays.
All data are provisional and subject to change.

SUMMARY

Current daily avg

CASES

**CASES BY ZIP** 

**TESTS** 

**VACCINES** 

**VACCINES BY ZIP** 



? Learn how to use this dashboard.

#### **盆 LABORATORY-CONFIRMED CASES**

403 ▼

420 (-4%)

715,827 Cumulative

14.9

Daily rate per

#### **HOSPITALIZATIONS**

28 V

Current daily avg

28 (-2%) Prior week

48,538 Cumulative

1.0

Daily rate per 100,000 Current daily avg

#### DEATHS


0.29 V


1.00 (-71%)


7,930

0.0

Prior week Cumulative Daily rate per 100.000







#### **■** VACCINATIONS ADMINISTERED

4,920 ▼ Current daily avg

5,551,502 Cumulative

71.1% Completed series

79.6% At least one dose 1.8% ▼

Current daily avg

**EMERGENCY ROOM VISITS** 

1.9%

Prior Week


#### HOSPITAL BEDS IN USE 1


3.6%


3.2%

Current daily avg

Prior Week







### Our local risk based on CDC COVID-19 Community Levels is:


## Medium

|  | New cases<br>per 100,000 population<br>(last 7 days) | New admissions<br>per 100,000 population<br>(last 7 days) | Percent of staffed inpatient beds occupied by COVID-19 patients (last 7 days) |
|--|--|---|---|
|  | [Goal is <200]                                       | [Goal is <10]   | [Goal is <10%]  |
| City of Chicago                            | 107  | 7.1   | 3.2%  |
| Cook County<br>(including City of Chicago) | 113  | 10.3  | 3.6%  |

Chicago metrics are calculated based on Chicago-level data.

Cook County metrics are calculated by the CDC and posted on the <u>CDC Community Levels website</u>. Data current as of 11/10/2022.







| WHO label  | Lineage # | US Class | %Total | 95%PI      |  |  |  |
|--|-----------|----------|--------|------------|--|--|--|
| Omicron  | BA.5      | VOC      | 29.7%  | 27.2-32.3% |  |  |  |
|  | BQ.1.1    | VOC      | 24.1%  | 21.3-27.3% |  |  |  |
|  | BQ.1      | VOC      | 20.1%  | 17.2-23.4% |  |  |  |
|  | BF.7      | VOC      | 7.8%   | 6.8-9.0%   |  |  |  |
|  | BA.4.6    | VOC      | 5.5%   | 5.0-6.2%   |  |  |  |
|  | BN.1      | VOC      | 4.3%   | 3.0-6.2%   |  |  |  |
|  | BA.5.2.6  | VOC      | 2.9%   | 2.5-3.4%   |  |  |  |
|  | BA.2      | VOC      | 1.3%   | 0.8-1.9%   |  |  |  |
|  | BA.2.75   | VOC      | 1.2%   | 1.0-1.5%   |  |  |  |
|  | BA.2.75.2 | VOC      | 0.9%   | 0.6-1.2%   |  |  |  |
|  | BA.4      | VOC      | 0.1%   | 0.1-0.1%   |  |  |  |
|  | BA.1.1    | VOC      | 0.0%   | 0.0-0.0%   |  |  |  |
|  | B.1.1.529 | VOC      | 0.0%   | 0.0-0.0%   |  |  |  |
|  | BA.2.12.1 | VOC      | 0.0%   | 0.0-0.0%   |  |  |  |
| Delta  | B.1.617.2 | VBM      | 0.0%   | 0.0-0.0%   |  |  |  |
| Other  | Other*    |          | 2.0%   | 1.1-3.3%   |  |  |  |
| * Enumerated lineages are US VOC and lineages circulating above 1% |           |          |        |            |  |  |  |

<sup>\*</sup> Enumerated lineages are US VOC and lineages circulating above 1% nationally in at least one week period. "Other" represents the aggregation of lineages which are circulating <1% nationally during all weeks displayed.</p>

AGO



0%

8/13/22

8/20/22

8/27/22



11/12/22

11/5/22

10/29/22

9/24/22

9/10/22

9/3/22

9/17/22

10/8/22

10/1/22

10/22/22

10/15/22


<sup>\*\*</sup> These data include Nowcast estimates, which are modeled projections that may differ from weighted estimates generated at later dates

<sup>#</sup> BA.1, BA.3 and their sublineages (except BA.1.1 and its sublineages) are aggregated with B.1.1.529. Except BA.2.12.1, BA.2.75, BA.2.75.2, BN.1 and their sublineages, BA.2 sublineages are aggregated with BA.2. Except BA.4.6, sublineages of BA.4 are aggregated to BA.4. Except BF.7, BA.5.2.6, BQ.1 and BQ.1.1, sublineages of BA.5 are aggregated to BA.5. For all the lineages listed in the above table, their sublineages are aggregated to the listed parental lineages respectively. Previously, BN.1 was aggregated with BA.2.75. Lineages BA.2.75.2, BN.1, BA.4.6, BF.7, BA.5.2.6 and BQ.1.1 contain the spike substitution R346T.

#### Current virus levels in wastewater by site

This metric shows whether SARS-CoV-2 levels at a site are currently higher or lower than past historical levels at the same site. 0% means levels are the lowest they have been at the site; 100% means levels are the highest they have been at the site. Public health officials watch for increasing levels of the virus in wastewater over time and use these data to help make public health decisions.

▲ Note: Sites began collecting data at different times. Sites that began reporting wastewater data after December 1, 2021 are not comparable to sites that started reporting data on or before December 1, 2021. The data history for these new sites is not long enough to reflect the same surges as the other sites.



Current SARS-CoV-2 virus levels by site, United States

| Current virus<br>evels category | Num.<br>sites | %<br>sites | Category<br>change in last 7<br>days |
|---------------------------------|---------------|------------|--------------------------------------|
| New Site                        | 71            | 8          | 9%                                   |
| 0% to 19%                       | 80            | 8          | - 29%                                |
| 20% to 39%                      | 327           | 35         | - 9%                                 |
| 40% to 59%                      | 301           | 32         | - 11%                                |
| 60% to 79%                      | 134           | 14         | 9%                                   |
| 80% to 100%                     | 29            | 3          | 4%                                   |

Total sites with current data: 942

Total number of wastewater sampling sites: 1249

How is the current SARS-CoV-2 level compared to past levels calculated?

Select legend categories to filter points on the map.



#### **Total Vaccine Doses**

Distributed 905,043,735

Administered 646,524,294

1.51M

Children < 5 years of age with at least one dose since June 18, 2022

See <u>Vaccination Demographic Trends</u> for more information.

31.4M

People ≥ 5 years of age with an updated (bivalent) booster dose<sup>‡</sup>

| Completed Primary Series | Updated (Bivalent) Booster<br>Dose     |
|--------------------------|--|
| Count                    | Percent of US Population               |
| 31,417,048               | 10.1%                                  |
| 31,136,841               | 11%                                    |
| 30,295,463               | 11.7%                                  |
| 14,764,441               | 26.9%                                  |
|                          | Count 31,417,048 31,136,841 30,295,463 |

About These Data | View Footnotes and Download Data

CDC | Data as of: November 9, 2022 6:00am ET. Posted: November 10, 2022






#### Reinfection Worse than Initial Infection?

- New analysis of large VA system shows SARS-CoV-2 reinfection is associated with increased risk of all-cause mortality, hospitalization and a wide range of long COVID complications compared to those with no reinfection
- Significant limitations wide to interpretation
  - Median age 60
  - 87% unvaccinated
  - Had to be documented reinfection with positive test





# How to incorporate COVID-19 vaccines into your daily practice





## Fall COVID-19 Vaccine "Reset"

With it being Fall and back to school using this time to reset/refresh ourselves: Prepare for cold and flu season

Utilize the fall to give COVID-19 vaccine boosters but all other vaccines and influenzas vaccines to our patients

Focus on getting COVID-19 primary series to any patient or parent in need

Educating staff, providers, parents and providers that COVID-19 boosters are coming for younger children





## Battling Vaccine Recommendation Fatigue

Clinicians and staff are growing tired and discouraged by the effort required to encourage some patients to get vaccinated.

When discussing the COVID vaccine, approach more as a human, less as a clinician:

- 1. Your patient can be your ally
- 2. Roll with resistance
- 3. Use personal stories but don't take it personal!
- 4. Keep the conversation going





## 10 Steps to Increase Vaccination

- School Located Vaccine Clinics
- Work- Place Vaccination
- Vaccine Requirements
- Effective Messenger
- Combating Misinformation

- Vaccine Ambassadors
- Clinical Practice
   Standardization
- Medical Reminders
- Motivational Interviewing
- Financial Incentives





## CDC Guidance to Immunization Practice

Planning Activities

Preclinic Activities

Clinical Day

Post-clinic






# New COVID-19 Providers Phase I: Routine Vaccine Planning Activities

### Clinic Challenges

- Need to get CDC approval
- ICARE access
- Order vaccine
- Education
  - Staff education
  - Storage
  - Ordering
- Need to observe patients
- COVID-19 Precautions

### Clinic Strengths

- Clinics have the knowledge and experience to vaccinate
- Utilize established primary care immunization models and strategies like with Influenza and HPV
- Are trusted members in the community patients want to be vaccinated in their medical home





# Phase I: Planning activities needed to incorporate COVID-19 vaccine into daily routine

### Leadership Roles/Responsibilities

- Reimbursement/Billing codes Updated
- VFC COVID-19 provider
  - Data requirement
  - Vaccine Handling
- Logistics
  - Injection only clinic
  - Anticipating increase daily workflow
- Training Staff

### Clinic Staffing

- Roles
  - PSR
  - Vaccinators
  - Billers and coders
- Clinical Education
  - COVID-19 Vaccine Immunization Schedule
  - Dose determined by age
  - Dose







Use your smartphone to tell CDC about any side effects after getting the COVID-19 vaccine. You'll also get reminders if you need a second vaccine dose.

When you get your
COVID-19 vaccination, ask
your healthcare provider
about getting started
with v-safe

Learn more about **v-safe** www.cdc.gov/vsafe














## **V-SAFE**





3. v-safe call center conducts active telephone follow-up on a clinically important event and takes a VAERS report if appropriate

**Call center** 





# Vax Verify

#### **How it works**

Take these four steps to view your immunization history.



#### **Register Yourself**

ter the name and address you use h your primary care provider. Take the time to get your information correct.



**Account Activation** 

Click the link in the registration email (check your spam folder). Complete password setup process.



#### **Identity Verification**

Proceed by answering questions to verify your identity. See FAQs for Experian identity verification details.



#### **View Immunizations**

See your immunization records. Print, download, and get your COVID SMART Health card!





# COVID-19 Clinic Supplies

#### **COVID-19 Supply Kits (optional)**

- Alcohol Pads
- Surgical masks/Face Shields
- Needles
- Syringes
  - 1 mL
  - 3 mL (reconstitution pack)
- Chart
  - Needle gauge and length
- CDC vaccine cards (100)

#### **Additional Clinic Supplies**

- Patient Care
  - Band-aids
  - Gauze
  - Treats/Stickers
  - Emergency Kit
- Office Supplies
  - Pens
  - Clip boards
  - Garbage bags





# How can providers and staff make COVID-19 vaccine administration easy?

- Incorporate clinical staff into the decision-making process regarding vaccine delivery or logistics?
  - Since it is Fall can we do more COVID-19 vaccines and flu shots in clinic?
- Unlike other vaccines we can pre-mix or pre-draw COVID-19 vaccine and they are good for 12 hours
- Premix COVID-19 vaccines for clinic day
- Important to make sure these pre-mixed vaccines are discarded at the end of clinical day
- Do you have a labeling system? What works for your group?





## Fall Reset

- Vaccine wastage is expected, and clinic will not be penalized
- Adopt practices that will work for your team
- Encourage staff, MA's, RN's and PSR to attend IVAC virtual bootcamps,
   IVAC Regional Advisor office hours, or these sessions
- Incentives with time off or lunch for time for job well done





## Storage & Handling Pfizer

| AGE INDICATIONS  | 6 months through<br>4 years      | 5 years through<br>11 years    | 5 years through<br>11 years     | 12 years<br>and older | 12 years<br>and older           |  |
|--|----------------------------------|--------------------------------|---------------------------------|-----------------------|---------------------------------|--|
| FORMULATION  | Primary Series                   | Primary Series                 | Single Bivalent<br>Booster Dose | Primary Series        | Single Bivalent<br>Booster Dose |  |
| VIAL CAP COLOR/<br>LABEL WITH<br>COLOR BORDER                | Maroon                           | Orange                         | Orange/<br>Bivalent label       | Gray                  | Gray                            |  |
| PREPARATION  | Dilute Before Use                | Dilute Before Use              | Dilute Before Use               | De Met Billete        | Do Not Dilute                   |  |
| AMOUNT OF DILUENT<br>NEEDED PER VIAL <sup>a</sup>            | 2.2 mL                           | 1.3 mL                         | 1.3 mL                          | Do Not Dilute         |                                 |  |
| DOSE VOLUME/DOSE   | 0.2 mL/3 mcg                     | 0.2 mL/10 mcg                  | 0.2 mL/10 mcg                   | 0.3 mL/30 mcg         | 0.3 mL/30 mcg                   |  |
| DOSES PER VIAL   | 10 primary<br>(after dilution)   | 10 primary<br>(after dilution) | 10 booster<br>(after dilution)  | 6 primary             | 6 booster                       |  |
| ULT FREEZER<br>(-90°C TO -60°C) <sup>b</sup>                 | 12 months                        |                                |                                 |                       |                                 |  |
| FREEZER<br>(-25°C TO -15°C)                                  |                                  | DO NOT STORE                   |                                 |                       |                                 |  |
| REFRIGERATOR<br>(2°C TO 8°C)                                 | 10 weeks                         |                                |                                 |                       |                                 |  |
| ROOM TEMPERATURE<br>(8°C TO 25°C)<br>including any thaw time | 12 hours prior to first puncture |                                |                                 |                       |                                 |  |
| AFTER FIRST<br>PUNCTURE<br>(2°C TO 25°C)                     | Discard after 12 hours           |                                |                                 |                       |                                 |  |


- Diluent: Sterile 0.9% Sodium Chloride Injection, USP. Do not use bacteriostatic 0.9% Sodium Chloride Injection or any other diluent.
- Regardless of storage condition, vaccines should not be used after 12 months from the date of manufacture printed on the vial and cartons.




## Pfizer Vaccine


- Primary series
  - Monovalent
- Bivalent
  - Original
  - Omicron

Monovalent label Primary series only Ages 12 years and older





Bivalent label Booster dose only Ages 12 years and older




Pfizer-BioNTech COVID-19 Vaccine Primary Series Only\*



Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original and Omicron BA.4/BA.5)

**Booster Dose Only\*** 





## Storage & Handling Moderna

| AGE INDICATIONS AND FORMULATION                              | 6 months through 5 years<br>(Primary Series) | 6 years through 11 years<br>(Primary Series)* |                |  |  |  |  |
|--|--|---|----------------|--|--|--|--|
| VIAL CAP COLOR   | Dark Blue                                    | Dark Blue                                     | Red (5.5 mL)   | Dark Blue  |  |  |  |
| VIAL LABEL<br>BORDER COLOR                                   | Magenta                                      | Purple  | Light Blue     | Gray   |  |  |  |
| PREPARATION  | Do Not Dilute                                | Do Not Dilute                                 | Do Not Dilute  | Do Not Dilute  |  |  |  |
| DOSE VOLUME/DOSE   | 0.25 mL/25 mcg                               | 0.5 mL/50 mcg                                 |                | <ul> <li>6 to 11 years old:</li> <li>0.25 mL/25 mcg</li> <li>12 years and older:</li> <li>0.5 mL/50 mcg</li> </ul> |  |  |  |
| DOSES PER VIAL   | DOSES PER VIAL 10 primary                    |   | 11 max primary | Varies by age: 6 to 11 years old: 10 booster 12 years and older: 5 booster   |  |  |  |
| ULT FREEZER<br>(-90°C TO -60°C)                              |  | DO NOT STORE                                  |                |  |  |  |  |
| FREEZER<br>(-50°C TO -15°C) <sup>a</sup>                     |  | Until expiration                              |                |  |  |  |  |
| REFRIGERATOR<br>(2°C TO 8°C)                                 |  | 30 days                                       |                |  |  |  |  |
| ROOM TEMPERATURE<br>(8°C TO 25°C)<br>including any thaw time |  | 24 hours                                      |                |  |  |  |  |
| AFTER FIRST PUNCTURE   | Discard after 12 hours                       |   |                |  |  |  |  |


- Regardless of storage condition, vaccines should not be used after the expiration date.
- b After a vial is punctured 20 times it should be discarded even if the 12-hour time limit has not been met.
- \* Can be used as a dose in those who received a J & J primary dose.
- \*\* Although labels may state "booster doses only", the blue cap, purple label border presentation is only for use as a primary dose in ages 6-11



(2°C TO 25°C)b



## Moderna Vials







## Preparing Vaccine

#### DO

- Allow the vaccine and diluent (if necessary) to come to room temperature
- Check the expiration dates of the vaccine and diluent BEFORE MIXING
- Only use diluent from a single draw

#### DO NOT

- Re-freeze thawed vaccines
- Combine residual vaccines from multiple vials to obtain a full dose
- Shake vaccines or diluent
- NEVER use expired vaccine or diluent





## Preparation Best Practices

- ▶ Prepare vaccines in a designated area away from any space where potentially contaminated items are placed
- Only prepare vaccines when you are ready to administer them
- ▶ Always check expiration dates and confirm that you have selected the correct vaccine
  - Confirm the product and dose are age-appropriate
- Extra care should be taken when preparing multi-dose vials in order to avoid contamination







## Premixed Pfizer







# Clinical Day: Pre-clinic Staff Huddle

#### Check in

- Need to complete Consent
  - Screening
- Receive VIS/ EUA
- Administrators
  - Give Consent
  - Start COVID-19 Vaccine card
  - Use pre-printed labels

#### Staff

- Reconstitution (Mixologists)
  - Reconstituting and labeling vaccine
- Vaccinators
  - Reviewing Consents
  - Giving vaccines
  - Document





## Clinical Day

#### **Clinical Flow**

- Check in
  - Need to complete Consent
  - Screening
- Receive EUA
- Administrators/PSR's/Front Desk
  - Give Consent
  - Start COVID-19 Vaccine card
- Observation

#### **Staff**

- Reconstitution (Mixologists)
  - Reconstituting and labeling vaccine
- Vaccinators
  - Reviewing Consents
  - Giving vaccines
  - Document





## Phase IV: Post Clinical Activities

- Debrief Huddle
  - Recap
- Vaccine Count
  - Vaccines used
  - Vaccines that were wasted
- Vaccine Handling/Storage
- Weekly Report Vaccine Stock on Vaccine finder
  - https://covid.locating.health/login
- Data Requirement
  - Need to document vaccine waste on ICARE
  - Can be done daily or weekly







# Phase IV: Reimbursement for Administration as of April 5<sup>th</sup>, 2022



#### **COVID-19 Coverage for the Uninsured**

The Federal HRSA COVID-19 Uninsured Program (UIP) stopped accepting claims for testing and treatment on March 22, 2022 and claims for vaccine administration on April 5, 2022 due to lack of funding. The Illinois Healthcare and Family Services (HFS) COVID-19 Uninsured Program is separate from the Federal HRSA program and will continue through the end of the federal public health emergency. This means you will still be reimbursed for some COVID-19 related services, like testing and vaccine administration for the uninsured. See memo here and more information about the HFS program below:

- This program reimburses providers for COVID-19 testing and testing-related services provided to uninsured individuals on or after March 18, 2020. Always check for existing Medicaid first.
- Reimbursement through this program is available regardless of income, citizenship, or immigration status.
- HFS will reimburse providers for COVID-19 testing and testing-related services at Medicare rates, when the code is listed on the <u>HFS COVID-19 Fee Schedule</u>, regardless of whether the service is provided via telehealth or face-to-face.
- Any codes not included on the COVID-19 Fee Schedule will be reimbursed at Medicaid rates.

Reminder: Check MEDI to see if the patient is already on Medicaid before using the uninsured portal. The rates are the same (Medicare). Alternative resources for uninsured individuals who need COVID-19 services or other health care coverage include: Medicaid enrollment, Healthcare marketplace enrollment, COVIDtests.gov, HRSA.gov





## **COVID-19 Providers**

HFS is paying providers \$42 administration fee for giving COVID vaccines!!!!!

#### **COVID-19 Vaccine Providers Remember:**

- COVID-19 vaccine must be provided free of charge to patients. Charging patients some or all of COVID-19 vaccine administration is a violation of federal law. It can be reported to the <u>HHS Office</u> of the Inspector General (OIG).
- Per the Centers for Disease Control and Prevention's Requirements for COVID-19 Vaccination
   Program Providers, providers must continue to administer COVID-19 vaccines at no out-of-pocket cost to recipients.
- All organizations and providers participating in the CDC COVID-19 Vaccination Program (which currently includes any provider administering COVID-19 vaccine): Must administer COVID-19 vaccine regardless of the vaccine recipient's ability to pay.





### Phase IV: Reimbursement for Administration

- Visit the <u>Illinois Department and Family Services (IHFS) website</u> and AAP resource for reimbursement information
  - Vaccine Counseling Coverage and Vaccine Additional Dose and Booster Dose Clarification added
- https://www2.illinois.gov/hfs/MedicalProviders/notices/Pages/prn22 0322a.aspx
- <a href="https://www.aap.org/en/pages/2019-novel-coronavirus-covid-19-infections/covid-19-vaccine-for-children/covid-19-vaccine-administration-getting-paid/">https://www.aap.org/en/pages/2019-novel-coronavirus-covid-19-infections/covid-19-vaccine-for-children/covid-19-vaccine-administration-getting-paid/</a>





# Some CPT Codes

ILLINOIS VACCINATES AGAINST COVID-19

| Vaccine Manufacturer              | Product<br>CPT | First Dose | Second Dose | Third Dose | Booster |
|-----------------------------------|----------------|------------|-------------|------------|---------|
| Pfizer Adult (grey cap)           | 91305          | 0051A      | 0052A       | 0053A      | 0054A   |
| Pfizer 5-11 (orange cap)          | 91307          | 0071A      | 0072A       | 0073A      | N/A     |
| Pfizer 6m-<5 (maroon cap)         | 91308          | 0081A      | 0082A       | N/A        | N/A     |
| Pfizer Bivalent Booster           | 91312          | 0124A      | N/A         | N/A        | N/A     |
| Moderna (Spikevax)                | 91301          | 0011A      | 0012A       | 0013A      | N/A     |
| Moderna (Spikevax) 6m-<br><6years | 91311          | 0111A      | 0112A       | 0113A      | N/A     |
| Moderna Bivalent Booster          | 91313          | 0134A      | N/A         | N/A        | N/A     |
| Janssen (Johnson & Johnson)       | 91303          | 0031A      | N/A         | N/A        | 0034A   |
| Novavax                           | 91304          | 0041A      | 0042A       | N/A        | N/A     |

# Questions?





# Next Session: Wednesday, November 30<sup>th</sup>

For any questions, email us at kshwest@peds.bsd.uchicago.edu



